PHENAPHEN NO.2 CAP 16.2 MG
PHENOBARBITAL : 16.2 MG CODEINE PHOSPHATE : 16.2 MG ACETYLSALICYLIC ACID : 325 MG · DIN 02042851 · WYETH-AYERST CANADA INC.
Health Canada status: CANCELLED POST MARKET
What is PHENAPHEN NO.2 CAP?
PHENAPHEN NO.2 CAP 16.2 MG contains PHENOBARBITAL : 16.2 MG CODEINE PHOSPHATE : 16.2 MG ACETYLSALICYLIC ACID : 325 MG. It is listed in the Health Canada Drug Product Database under DIN 02042851, held by WYETH-AYERST CANADA INC., supplied as CAPSULE for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 30-Aug-2001. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02042851 |
|---|---|
| Brand name | PHENAPHEN NO.2 CAP |
| Generic / active ingredient | PHENOBARBITAL : 16.2 MG CODEINE PHOSPHATE : 16.2 MG ACETYLSALICYLIC ACID : 325 MG |
| Manufacturer | WYETH-AYERST CANADA INC. |
| Strength | 16.2 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | NARCOTICS (CDSA I) |
| ATC code | N02AA79 CODEIN, COMBINATIONS WITH PSYCHOLEPTICS |
| AHFS class | 28:08.08 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 30-Aug-2001 |
| Original market date | 1999-04-12 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code N02AA79 CODEIN, COMBINATIONS WITH PSYCHOLEPTICS. 6 of 17 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-BUTALBITAL-ACETYLSALICYLIC ACID-CAFFEINE-CODEINE-C 1/2 | 50 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02554623 |
| APO-BUTALBITAL-ACETYLSALICYLIC ACID-CAFFEINE-CODEINE-C 1/4 | 15 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02554615 |
| FIORINAL-C 1/2 | 330 MG | CAPSULE | ARALEZ PHARMACEUTICALS CANADA INC | MARKETED | DIN 00176206 |
| FIORINAL-C 1/4 | 40 MG | CAPSULE | ARALEZ PHARMACEUTICALS CANADA INC | MARKETED | DIN 00176192 |
| TEVA-TECNAL C 1/2 | 40 MG | CAPSULE | TEVA CANADA LIMITED | MARKETED | DIN 00608181 |
| TEVA-TECNAL C 1/4 | 40 MG | CAPSULE | TEVA CANADA LIMITED | MARKETED | DIN 00608203 |
| PHENAPHEN NO 2 CAP | 16.2 MG | CAPSULE | AYERST LABORATORIES | CANCELLED POST MARKET | DIN 01909290 |
| PHENAPHEN NO 3 CAP | 16.2 MG | CAPSULE | AYERST LABORATORIES | CANCELLED POST MARKET | DIN 01909312 |
| PHENAPHEN NO 4 CAP | 64.8 MG | CAPSULE | AYERST LABORATORIES | CANCELLED POST MARKET | DIN 01909304 |
| PHENAPHEN NO.3 CAP | 325 MG | CAPSULE | WYETH-AYERST CANADA INC. | CANCELLED POST MARKET | DIN 02042878 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.